NEW YORK (GenomeWeb News) – Miraculins this week said that it has received gross proceeds of C$554,000 (US$569,000) from the exercise of 5,540,000 warrants through its previously announced warrant exercise incentive program. The firm launched the early-exercise program last month and had targeted the early exercise of up to 7.8 million of its outstanding unlisted warrants.
Biomoda said this week that it has been accepted as an associate member of the National Cancer Institute's Early Detection Research Network, which brings together institutions and companies to accelerate the research and development of biomarkers and other technologies for the early detection of cancer.
The Ontario Institute for Cancer Research has enhanced its Intellectual Property development and Commercialization program, now called the IPDC Fund, the institute said this week. Under the program, the institute will make $1.5 million available over three years for each eligible project, with additional equity investments possible. The fund was set up to offer support to Ontario-based projects working on anti-cancer technologies.
Abcodia, a UK-based firm working on the validation and discovery of molecular biomarkers, was launched this week. The firm has been granted rights to commercialize intellectual property from one of the UK's largest biobanks, which has been created by scientists at University College London. Abcodia said that it is seeking commercial and academic partners. The firm's CEO is Julie Barnes, formerly chief scientific officer at BioWisdom, who also previously worked in R&D at GlaxoSmithKline.
The Massachusetts Life Sciences Center this week announced the launch of an open solicitation for life sciences-related capital projects beginning in fiscal-year 2013. It has set aside up to $25 million in capital dollars for this initial solicitation, which is aimed at life sciences entities planning expansion in the state.